Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Recruiting 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 311Leukemia, Lymphocytic, Chronic, B-Cell 108Myelodysplastic Syndromes 63Leukemia 43Recurrence 42Precursor Cell Lymphoblastic Leukemia-Lymphoma 41Neoplasms 27Leukemia, Myelomonocytic, Chronic 27Lymphoma, Non-Hodgkin 21Hematologic Neoplasms 20Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 17Leukemia, Biphenotypic, Acute 16Leukemia, Myeloid 11Neoplasm, Residual 10Myeloproliferative Disorders 10Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Multiple Myeloma 9Lymphoma, Mantle-Cell 8Lymphoma 8Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 7Lymphoma, Large B-Cell, Diffuse 6Lymphoma, B-Cell, Marginal Zone 6Chromosome 17 deletion 6Lymphoma, Follicular 5Lymphoma, B-Cell 5Leukemia, B-Cell 5Burkitt Lymphoma 5Primary Myelofibrosis 4GATA2 Deficiency 4Blast Crisis 4

Interventions

Cytarabine 7Mitoxantrone 3Cyclophosphamide 3venetoclax 2thymoglobulin 2fludarabine phosphate 2fludarabine 2devimistat 2Thiotepa 2Tacrolimus 2Rituximab 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2Daunorubicin 2Cladribine 2vosaroxin 1quizartinib 1plerixafor 1pegylated granulocyte colony-stimulating factor 1blinatumomab 1aldesleukin 1Transplantation 1Stem Cell Transplantation 1Sorafenib 1Sirolimus 1Razoxane 1Mycophenolic Acid 1Metformin 1Mesna 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Sarcoma, Myeloid × venetoclax × Other hematologic neoplasm × Clear all
NCT04797767 2026-04-17

Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

University of Washington

Phase 1/2 Recruiting
62 enrolled
Other hematologic neoplasmSarcoma

Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Kura Oncology, Inc.

Phase 1 Recruiting
420 enrolled
Other hematologic neoplasmSarcoma

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡